Is Pleased to Announce A Seminar
Presented by

M. Kyle Hadden
University of Connecticut

Friday, September 8, 2017
At 11:30 am
Astellas Conference Room
SLSRC 3410/3430

"Design and Development of Targeted Anti-Cancer Chemotherapeutics"

Research in the Hadden lab focuses primarily on the design, synthesis, and in vitro evaluation of novel small molecules as anti-cancer chemotherapeutics. This seminar will describe our recent work developing inhibitors of two distinct molecular targets, the hedgehog (Hh) signaling pathway and translesion synthesis (TLS). Dysregulation of the Hh pathway has been linked to the development of multiple forms of cancer; most notably, basal cell carcinoma and medulloblastoma. I will detail our recent structure-activity relationship studies designed to repurpose the clinically efficacious anti-fungal itraconazole as an Hh pathway inhibitor. With respect to TLS, recent studies have demonstrated that functional TLS reduces the cytotoxic properties of platinating agents and can introduce acquired resistance against standard anti-cancer regimens. As such, developing new small molecules to target TLS has recently emerged as a promising strategy for enhancing the efficacy of platinating and alkylating agents. Our recent work developing small molecule scaffolds that disrupt a key protein-protein interaction in the TLS pathway will be described.

Refreshments will be served at 11:15 am